<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708329</url>
  </required_header>
  <id_info>
    <org_study_id>TvsMC 1.0</org_study_id>
    <nct_id>NCT02708329</nct_id>
  </id_info>
  <brief_title>T-provisional Stenting vs Mini-Crush in Chronic Total Occlusions (CTO)</brief_title>
  <official_title>Results of T-provisional and Mini Crush Stenting in Patients With Bifurcation Lesions After Chronic Coronary Arteries Occlusions Recanalization: A Prospective Randomized Single-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <brief_summary>
    <textblock>
      The aim is to compare the results of using T-provisional and Mini-Crush stenting techniques
      in patients with bifurcation lesions in the CTO segment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>During 1 year after procedure</time_frame>
    <description>Primary outcome is defined as a composite endpoint of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>During 1 year after procedure</time_frame>
    <description>Major adverse cardiac and cerebrovascular events (MACCE) including: including: All-cause mortality, Myocardial infarction, Stent thrombosis, Clinically indicated Target lesion revascularization, Any target lesion revascularization, Any target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis of main vessel/side branch</measure>
    <time_frame>At 12-month follow-up</time_frame>
    <description>Angiographically estimated main vessel/side branch restenosis. Restenosis is defined as â‰¥ 50% diameter lumen loss in a target lesion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Coronary Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>CTO coronary angioplasty +T-provisional stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTO coronary angioplasty + Mini-crush stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-provisional stenting</intervention_name>
    <description>Standard endovascular T-provisional stenting technique</description>
    <arm_group_label>CTO coronary angioplasty +T-provisional stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mini-crush stenting</intervention_name>
    <description>Standard endovascular Mini-crush stenting technique</description>
    <arm_group_label>CTO coronary angioplasty + Mini-crush stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTO coronary angioplasty</intervention_name>
    <description>A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.</description>
    <arm_group_label>CTO coronary angioplasty +T-provisional stenting</arm_group_label>
    <arm_group_label>CTO coronary angioplasty + Mini-crush stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients considered for coronary angioplasty with stenting due to Ischemic heart
             disease (Stable angina, Unstable angina, non-ST Myocardial Infarction).

          -  Bifurcation side branch diameter &gt;2 mm in CTO segment, verified by coronary
             angiography

          -  Successful CTO recanalization

          -  Signed, documented informed consent prior to admission to the study

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;75 years

          -  Left main artery bifurcation lesion

          -  Reocclusion CTOs

          -  Renal insufficiency (GFR/MDRD &lt;30 ml/min)

          -  Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

          -  Known non-adherence to double anti-platelet therapy (DAPT)

          -  LVEF &lt;30%

          -  Continuing bleeding

          -  Acute coronary syndrome (ST-elevation Myocardial infarction)

          -  Anamnesis of previous CABG

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State Research Institute of CIrculation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>May 8, 2016</last_update_submitted>
  <last_update_submitted_qc>May 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary stenosis</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Coronary angioplasty with stenting</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <keyword>Chronic total occlusion</keyword>
  <keyword>Bifurcational lesion</keyword>
  <keyword>Bifurcational stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

